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The increasing number of treatment options for patients with metastatic carcinomas has created a concomitant need for
new methods to monitor their use. Ideally, these modalities would be noninvasive, be independent of treatment, and provide
quantitative real-time analysis of tumor activity in a variety of carcinomas. Assessment of circulating tumor cells (CTCs) shed into
the blood during metastasis may satisfy this need. We developed the CellSearch System to enumerate CTC from 7.5mL of venous
blood. In this review we compare the outcomes from three prospective multicenter studies investigating the use of CTC to monitor
patients undergoing treatment for metastatic breast (MBC), colorectal (MCRC), or prostate cancer (MPC) and review the CTC
deﬁnition used in these studies. Evaluation of CTC at anytime during the course of disease allows assessment of patient prognosis
and is predictive of overall survival.
1.Introduction
In 1869 Thomas Ashworth, an Australian physician, after
observing microscopically circulating tumor cells in the
blood of a man with metastatic cancer, postulated that “....
cells identical with those of the cancer itself being seen in the
blood may tend to throw some light upon the mode of origin
of multiple tumours existing in the same person.” After
comparing the morphology of the circulating cells to tumor
cells from diﬀerent lesions Ashworth concluded that “One
thing is certain, that if they [CTC] came from an existing
cancer structure, they must have passed through the greater
part of the circulatory system to have arrived at the internal
saphena vein of the sound leg” [1]. Over the succeeding
one hundred and forty years, cancer research has indeed
demonstrated the critical role circulating tumor cells play in
the metastatic spread of carcinomas [2]. However, it has only
been shown recently—after development of technologies
with the requisite sensitivity and reproducibility—that the
diagnostic potential of these rare cells could be exploited [3–
7].
To date, a variety of research methods have been
developed to isolate and enumerate CTC [8]. The CellSearch
Circulating Tumor Cell System has been validated via a
rigorous clinical testing program [9–18] and is the only
FDA cleared device for the enumeration of CTC in whole
blood. The signiﬁcance of the CellSearch assay results has
been amply demonstrated, ﬁrst in an extensive pilot study
program and then in a series of prospective, well-controlled
pivotal clinical trials. It is the agreement seen between
CTC levels in patients with metastatic breast, colorectal, or
prostatecancerandthetrueclinicalendpointoverallsurvival
t h a tw ew i l lr e v i e w .
2.MaterialsandMethods
2.1. Study Design. Three prospective trials were conducted
in clinical centers throughout the United States, The Nether-
lands, and the UK to evaluate the ability of CTC to predict
PFS (Progression Free Survival) and OS (Overall Survival) in
patients with MBC, MCRC, and MPC cancer. The principal
inclusion criteria for the MBC and MCRC trials were2 Journal of Oncology
measurable disease, while all patients in the MPC study
had castration resistant disease deﬁned as two consecutive
increases in PSA despite standard hormonal management.
Patients commencing a new ﬁrst- or second-line cytotoxic
therapy for MPC or MCRC and any new line of therapy for
MBC were eligible. All patients had an ECOG performance
status score of 0 to 2 and hemoglobin ≥8g/dL. Patients with
brain metastases or a history of other malignancies within
the last ﬁve years were excluded.
All patients were enrolled on an Intent-to-Treat basis.
The institutional review boards at each center approved the
study protocol and all patients provided written informed
consent. The CellSearch system was used to enumerate CTC
in177MBC,430MCRC,and231MPCpatients,respectively.
7.5mL of blood was drawn from patients before starting a
new line of therapy and at monthly intervals after initiation
of therapy [10–16]. An independent clinical research orga-
nization collected and monitored all clinical and laboratory
data. Patients were followed up with regular chart review
for up to 36 months from the time of the baseline blood
draw for the survival analysis. For post-treatment samples,
the measurement was taken from the time of the sample to
a v o i dl e a dt i m eb i a s .P a t i e n t sw e r ec a t e g o r i z e dp r o s p e c t i v e l y
as having either Unfavorable or Favorable CTC counts.
For MBC and MPC, Unfavorable CTC were deﬁned as
≥5CTC/7.5mL and for MCR ≥3CTC/7.5mL.
2.2. Enumeration of Circulating Tumor Cells. Blood sam-
ples were drawn into 10mL evacuated blood draw tubes
(CellSave, Veridex, Raritan, NJ), maintained at room tem-
perature, and processed within 96 hours of collection.
The evaluations were performed in a blinded fashion in
one of four central laboratories (Veridex LLC, Hunting-
don Valley, PA; Veridex LLC, Enschede, The Netherlands;
IMPATH Predictive Oncology, Los Angeles, CA; and Cleve-
landClinic,Cleveland,OH).TheCellSearchSystem(Veridex
LLC, Raritan, NJ) consists of the CellTracks Autoprep,
CellTracks Magnest, CellSearch Epithelial Cell Kit, and
the CellTracks Analyzer II. The CellSearch Epithelial Cell
Kit contains ferroﬂuids labeled with the epithelial cell
adhesion molecule (EpCAM), the staining reagents 4 ,2-
diamidino-2-phenylindole, dihydrochloride (DAPI), CD45-
Allophycocyan(CD45-APC),andcytokeratin8,18Phycoery-
thrin and cytokeratin 19 Phycoerythrin (CK-PE), buﬀers to
enhancethecellcapture[19,20],and permeabilizes and ﬁxes
the cells.
The CellTracks Autoprep immunomagnetically enriches
cells expressing EpCAM from 7.5mL of blood, ﬂuorescently
labels the enriched cells with DAPI, CD45-APC, and CK-
PE, and resuspends the cells in the cartridge placed in
the CellTracks Magnest. The design of the magnets guides
the magnetically labeled cells to the analysis surface [21]
and the CellTracks Magnest containing the chamber is
placed on the CellTracks Analyzer II. This semiautomated
ﬂuorescence-based microscopy system acquires images using
a 10X NA0.45 objective with ﬁlters for DAPI, FITC (not
used), PE and APC to cover the complete surface area of
the analysis chamber. A computer identiﬁes objects staining
with DAPI and PE in the same location and generates images
for the DAPI, FITC, PE, and APC ﬁlters. A reviewer selects
the CTC deﬁned as nucleated DAPI+ cells, lacking CD45
and expressing CK-PE from the gallery of objects which
are tabulated by the computer. Accuracy, precision, linearity,
and reproducibility of the CellSearch have been described
elsewhere [17].
2.3. Statistical Analysis. For this study Kaplan-Meier plots
were generated based on CTC at baseline and follow-up
blood collections for survival analyses. Survival curves were
compared using log-rank testing. Cox proportional hazards
regression was used to determine univariate and multivariate
hazards ratios for overall survival.
3. Results
3.1. Classiﬁcation of Circulating Tumor Cells. Deﬁnitions of
CTC vary widely between studies and have lead to a large
range of reported CTC frequencies. CellSearch provides a
highlystandardized andautomatedplatformtodetect tumor
cells in whole blood. In the CellSearch system ﬁnal classiﬁca-
tion of CTC is performed by the operator and is the main
contributor of the error of the assay [22]. Consistency in
CTC classiﬁcation among operators is therefore important.
To illustrate that this can be challenging is illustrated by the
images of 24 CTC candidates in Figure 1. Green represents
the CK-PE staining and purple the DAPI staining. The
corresponding APC and FITC images of the 24 candidates
showed no staining. Only objects that are larger in size than
the 4×4μm yellow boxes can be classiﬁed by the operators as
CTC.Mostoperatorswillhavenoproblemsassigningobjects
1–8 as CTC and will discard objects 21–24. The latter is
presented to the operator because of the presence of DAPI
in the vicinity of a CK-PE positive object. Disagreement can
occur when objects 9–20 are classiﬁed. Six operators that
classiﬁed CTC in the three prospective multicenter studies
were asked to classify the objects in Figure 1. The granulated
objects in frames 9–12 clearly show features consistent with
apoptosis [23]. All operators classiﬁed objects 9 and 10 as a
CTC,1of6classiﬁedobjects11asaCTC,and5of6classiﬁed
objects 12 as a CTC. The small objects 13–16 were classiﬁed
as CTC by all operators. Similar to the objects 9–12, objects
17–20 show the granulated CK-PE only; now the objects are
smaller. All operators classiﬁed object 17 as a CTC, none
classiﬁed object 20 as a CTC, and 5 of 6 classiﬁed objects 18
and 19 as a CTC.
3.2. Frequency of Circulating Tumor Cells in Cancer Patients
and Controls. The frequency of CTC in 7.5mL of blood
from 295 normal donors, 255 patients with benign disease,
and 177 MRC, 413 CRC, and 218 MPC patients before
initiation of a new line therapy is shown in Table 1.O n l y
a small fraction of the objects presented by the computer
to the operator are classiﬁed as CTC. This is illustrated in
Table 2 showing the average, standard deviation, and median
number of events detected by the software as CK+ and
DAPI+ in blood from normal donors, patients with benign
disease, MBC, MCRC, and MPC patients with 0 CTC, 1–4
CTC, and 5 or more CTC in 7.5mL of blood.Journal of Oncology 3
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Figure 1: Images of twenty-four CTC candidates identiﬁed by the CellTracks Analyzer II. The images show an overlay of DAPI purple and
CK-PE green. No staining was observed in the CD45 APC and FITC channel at the position of the CTC candidates. Six operators trained to
review CellSearch CTC data classiﬁed objects 1–10, 13–17 as CTC, and discard objects 20–24 as CTC. 1 of 6 operators classiﬁed object 11 as
a CTC and 5 of 6 operators classiﬁed object 12, 18, and 19 as a CTC.
Table 1: Frequency of CTC in 7.5mL of blood from normal donors: patients with benign disease and metastatic breast, colorectal, and
prostate cancer patients before initiation of a new line therapy.
Percentage of patients with CTC above threshold
#p a t ≥1 ≥5 ≥10 ≥50 ≥100 ≥500 ≥1000
Normal 295 3.4 0.0 0.0 0.0 0.0 0.0 0.0
Benign 255 7.5 0.4 0.4 0.0 0.0 0.0 0.0
Breast 177 70.6 49.7 38.4 20.9 15.8 3.4 2.8
Colorectal 413 47.5 18.2 11.6 2.4 1.0 0.0 0.0
Prostate 218 77.5 57.3 45.0 20.6 13.8 3.7 2.3
Table 2:FrequencyofeventsdetectedbythesoftwareasCK-PE+andDAPI+thatwerenotclassiﬁedasCTCin7.5mLofbloodfromnormal
donors: patients with benign disease, and metastatic breast, colorectal and prostate cancer patients before initiation of a new line therapy.
CTC
0 ≥1–<5 ≥5
n mean SD med n mean SD med n mean SD Med
Normal 285 53 68 40 10 81 108 42 0 — — —
Benign 236 38 30 30 18 44 26 47 1 159 — 159
Breast 50 53 29 29 36 73 93 38 86 403 1182 84
Colorectal 217 223 1070 78 121 266 468 116 75 603 1620 230
Prostate 49 420 1713 86 44 222 358 101 125 1301 3020 4124 Journal of Oncology
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Figure 2: Kaplan Meier Analysis of overall survival before starting a new line of therapy for patients with metastatic breast cancer (a),
metastaticcolorectal cancer (b),andcastration resistant prostatecancer (c).Patients were divided intothosewithFavorable andUnfavorable
CTC.Thecutoﬀvalue between favorable and unfavorable CTC was ≥5CTC/7.5mLbloodforbreastandprostatecancerand ≥3CTC/7.5mL
blood for prostate cancer.
3.3.RelationbetweenthePresenceofCTCandOverallSurvival
(OS) in MBC, MCRC, and MPC. For MBC and MPC
a threshold of 5CTC/7.5mL and for MCRC a threshold
of 3CTC/7.5mL were used to stratify patients into those
w i t hF a v o r a b l eo u t c o m e s( C T C<3o r<5) and those with
Unfavorable outcomes (CTC ≥3o r≥5). The Kaplan Meier
curves in Figure 2 show the probability of OS for patients
with Favorable and Unfavorable CTC counts before the
initiation of therapy. Median OS for MBC, MCRC, and
MPC patients with Favorable CTC was 21.9 (95% CI: 20.1–
28.6), 18.5 (95% CI: 15.2–21.2), and 21.7 (95% CI: 21.3–
NR) months, respectively. In contrast median OS for MBC,
MCRC, and MPC patients with Unfavorable CTC was 10.9
(95% CI: 7.0–15.2), 9.4(95% CI: 7.5–11.6), and 11.5 (95%
CI: 9.3–13.7) months, respectively. The diﬀerences are highly
signiﬁcant with logrank P-values <.0001.
Figure 3showstheKaplanMeiercurvesoftheprobability
of OS for patients with Favorable and Unfavorable CTC
counts at monthly intervals after initiation of therapy. At
all time points tested the diﬀerence in survival between
the Favorable and Unfavorable groups is highly signiﬁcant
(logrank P-values ≤.0070). CTCs thus predict outcomes at
any time during treatment and can be used to monitor
treatment.
To answer whether or not a change in CTC “after”
treatment can alter survival prospects, further Kaplan Meier
analyses were performed and shown in Figure 4. Patients
were divided into four groups: (1) CTCs remain Favorable
(green lines); (2) CTCs remain Unfavorable (red lines);
(3) CTCs change from Favorable to Unfavorable (orange
lines); (4) CTCs change from Unfavorable to Favorable
during the course of therapy (blue lines). In all three
cancers, patients with persistent CTC counts had the worst
outcome and strongly suggested that they were on a futile
therapy. Also patients that develop CTC during the course
of therapy convert to a poor prognosis, similar to thoseJournal of Oncology 5
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Figure 3: Kaplan Meier Analysis of overall survival. Favorable CTCs are indicated with 1 through 4 and Unfavorable CTCs with 5 through
8. (a) Median overall survival of MBC patients with Favorable CTC after 3–5 Weeks (1) (n = 92), 6–8 Weeks (2) (n = 77), 9–14 Weeks (3)
(n = 105) and 15–20 Weeks (4) (n = 70) of treatment median was 21.7, 19.1, 20.8, and 20.1 months, respectively. Median overall survival
of MBC patients with Unfavorable CTC after 3–5 Weeks (5) (n = 40), 6–8 Weeks (6) (n = 22) 9–14 Weeks (7) (n = 24), and 15–20 Weeks
(8) (n = 15) of treatment was 6.2, 6.3, 6.4, and 11.3 months, respectively. (b) Median overall survival of MCRC patients with Favorable CTC
after 1–2 Weeks (1) (n = 316), 3–5 Weeks (2) (n = 292), 6–12 Weeks (3) (n = 285), and 13–20 Weeks (4) (n = 172) of treatment was 15.7,
16.4, 15.8, and 14.6 months, respectively. Median overall survival of MCRC patients with Unfavorable CTC after 1–2 Weeks (5) (n = 41)
3–5 Weeks (6) (n = 41), 6–12 Weeks (7) (n = 25), and 13–20 Weeks (8) (n = 21) of treatment median was 6.1, 4.4, 3.3, and 3.3 months,
respectively. (c) Median overall survival of MPC patients with Favorable CTC after 2–5 Weeks (1) (n = 123), 6–8 Weeks (2) (n = 110), 9–12
Weeks (3) (n = 100), and 13–20 Weeks (4) (n = 99) of treatment median was 20.7, 19.9, 19.6, and 19.8 months, respectively. Median overall
survival of MPC patients with Unfavorable CTC after 2–5 Weeks (5) (n = 80), 6–8 Weeks (6) (n = 53), 9–12 Weeks (7) (n = 49), and 13–20
Weeks (8) (n = 44) of treatment was 9.5, 8.5, 7.6, and 6.7 months, respectively. The cutoﬀ value between favorable and unfavorable CTC was
≥5CTC/7.5mL blood for breast and prostate cancer and ≥3CTC/7.5mL blood for prostate cancer.
with Unfavorable CTC before and after therapy. In contrast
patient’s prognosis improved for those converting from the
Unfavorable to the Favorable group. This was the strongest
for MPC.
In both univariate and multivariate analysis CTC levels
at all time points were signiﬁcantly associated with overall
survival [10, 13, 15].
4. Discussion
In most cases death from cancer is not caused by expansion
of the primary tumor, but through dissemination of the
disease. To settle in distant sites tumor cells must travel
through the peripheral blood; question is at what frequency.
In routine analysis of 104 leukocytes (∼1μLo fb l o o d )t u m o r
cells are not observed. Using immunomagnetic enrichment
from 20mL of blood followed by ﬂowcytometric analysis we
were able to identify CTCs in blood from most carcinoma
patients [24, 25].
To minimize error in CTC enumeration the sample
preparation steps needed to be automated. A blood volume
of 7.5mL was chosen for the development of the standard-
ized CellSearch CTC enumeration system as this could be
routinely obtained from a 10mL draw tube. The automated6 Journal of Oncology
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Figure 4: CTC changes after treatment in patients with MBC (a), MCRC (b), and MPC (c). Curves labeled 1 represent patients with CTCs
that remain Favorable, labeled 2 CTCs convert from Unfavorable to Favorable, labeled 3 CTCs convert from Favorable to Unfavorable, and
labeled 4 CTC remain Unfavorable. (a) After initiation of therapy, CTC in 83 (47%) MBC remained Favorable with median overall survival
(OS) of 22.6 months, CTC in 39 (22%) patients remained Unfavorable median OS 4.1 months, CTC in 38 (21%) patients converted to
Favorable CTC median OS 19.8 months, and CTC converted to Unfavorable in 17 (10%) patients median OS 10.6 months. (b) CTC in 303
(70%) MCRC remained Favorable median OS 18.6 months, CTC in 24 (6%) patients remained Unfavorable median OS 3.9 months, CTC
in 74 (17%) patients converted to Favorable CTC median OS 11.7 months, and CTC converted to Unfavorable in 29 (7%) patients median
OS 7.1 months. (c) CTC in 88 (38%) MPC remained Favorable median OS of more than 26 months, CTC in 71 (31%) patients remained
Unfavorable median OS 6.8 months, CTC in 45 (20%) patients converted to Favorable CTC median OS 21.3 months, and CTC converted
to Unfavorable in 26 (11%) patients median OS 9.3 months. The cutoﬀ value between favorable and unfavorable CTC was ≥5CTC/7.5mL
blood for breast and prostate cancer and ≥3CTC/7.5mL blood for prostate cancer.
system utilizes immunomagnetic nanoparticles directed
against the epithelial cell adhesion molecule (EpCAM) to
isolate and concentrate epithelial tumor cells [17, 19]. Once
enriched, the cells are identiﬁed using epithelial cell speciﬁc
ﬂuorescently labeled anticytokeratin (CK) monoclonal anti-
bodies, the nuclear stain (DAPI), and absence of the pan-
leukocyte counter stain (CD45-APC). It should be noted
that assay success is dependent upon the level of expression
of the EpCAM and Cytokeratin target antigens which can
vary signiﬁcantly [8]. We have investigated these issues and
have demonstrated that although antigen expression varies
considerable, the assay is capable of functioning within a
wide range of EpCAM and cytokeratin levels [19, 20].
To reduce the background observed in blood from
healthy donors ﬂowcytometry used in our original work [24,
25] was replaced by ﬂuorescence microscopy. The addition
of morphology to the CTC deﬁnition indeed increased the
speciﬁcity but was accompanied by a reduction of the CTC
frequency in cancer patients. In model systems 1 tumor
cell spiked into 7.5mL of blood containing ∼ 5 × 107
leukocytes and 4 × 1010 erythrocytes can be identiﬁed and
recovery of spiked tumor cells is ∼80% [17, 19, 20]. WhereasJournal of Oncology 7
the morphology of cells from tumor cell lines is relatively
homogenous, a large heterogeneity is observed in tumor cells
in blood from cancer patients. This heterogeneity introduces
variation in the assignment of EpCAM+, Cytokeratin 8,18,
or 19, CD45−, DAPI+ objects as CTC by the operator [22].
The most likely explanation for the large variation in the
reported frequency of CTC by diﬀerent methods using a
similar phenotypic deﬁnition is the diﬀerences in the actual
deﬁnition of a CTC [23–30]. That less stringent criterion
for CTCs results in a signiﬁcant increase in the reported
n u m b e r sa si l l u s t r a t e di nTable 2 showing the number of
EpCAM enriched CK+DAPI+ events for patients with zero,
1–4, and 5 or more CTC. The CellSearch deﬁnition of a CTC
was set before the initiation and validated by prospective
clinical studies in MBC, MCRP, and MPC. Further studies
will be needed to determine the value, if any, of the
CK+ DAPI+ events detected that were not classiﬁed as
CTC.
The prospective multicenter studies in MBC, MCRC,
and MPC demonstrated that presence of CTC was a strong
predictor of poor outcome; see Figure 2.E v e na f t e raf e w
weeks of therapy, patients with Unfavorable CTC had much
shorter overall survival than did patients with Favorable
CTC; see Figure 3.E ﬀective therapies—ones that result in
elimination of CTC—can prolong survival, irrespective of
the line of therapy, as shown by the improvement in overall
survival in patients with MBC, MCRC, and MPC that
converted from an Unfavorable to Favorable CTC count;
see Figure 4. This beneﬁt was seen in patients independent
of line of therapy, indicating that treatment can still be
eﬀective in patients that have failed a previous therapy.
Today, the current standard of care calls for routine
assessments of a patient’s clinical status at or about one-
month intervals depending on the type of therapy. Imaging
studies are an exception as they are usually performed
at some intermediate time point and at the end of a
given line of therapy. Consequently most clinicians do
not entertain a change in treatment until after several
cycles of drug have been administered. It is also felt that
a certain minimum time, usually two to three cycles of
therapy is often needed before clinical beneﬁt may be
evident. Thus the advantages associated with changing
treatment at a signiﬁcantly earlier time point must be
demonstrated.
In this review we only addressed the clinical relevance of
CTC detected in patients with metastatic disease. Although
CTC can also be detected with the CellSearch in the adjuvant
setting and primary setting albeit at a lower frequency, no
prospective clinical trials have been concluded to determine
its clinical relevance [31].
5. Conclusions
CellSearch is a validated system to enumerate Circulating
Tumor Cells in 7.5mL of blood. In prospective multicenter
studies in metastatic breast, colorectal, and prostate cancer
the presence of CTC before and after initiation of a new
line of therapy was the strongest predictor of poor overall
survival.
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